Alterations in quadriceps muscle cellular and molecular properties in adults with moderate knee osteoarthritis

B. Noehren †a, K. Kosmac †a, R.G. Walton †, K.A. Murach †, M.F. Lyles ‡, R.F. Loeser §, C.A. Peterson †b, S.P. Messier ||b

† Department of Rehabilitation Sciences, College of Health Sciences, Center for Muscle Biology, University of Kentucky, Lexington, KY, 40536, USA
‡ Section on Gerontology and Geriatrics, Wake Forest School of Medicine, Winston-Salem, NC, 27109, USA
§ Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, 27599, USA
|| J.B. Snow Biomechanics Laboratory, Department of Health & Exercise Science, Wake Forest University, Winston-Salem, NC, 27109, USA

Keywords: Osteoarthritis
Atrophy
Fibrosis
Quadriceps weakness
Knee

Introduction

Knee osteoarthritis (OA) is a leading cause of disability worldwide1–4. While the development of knee OA is multifactorial, alterations in loading of the knee are believed to be an important contributor5,6. The quadriceps muscle plays a central role in modulating loads across the knee joint, and weakness contributes to pain and loss of function in people with knee OA7–9. The quadriceps muscle can be up to 40% weaker in OA patients compared to healthy individuals10–12. Quadriceps weakness is generally attributed to pain and atrophy due to inactivity12–16. However, the relationship between pain and atrophy to reduced strength in knee OA is not always strong13,14. For example, even when controlling for pain and activity levels, patients with knee OA have weaker quadriceps than controls15, and the progression of OA-mediated muscle weakness appears dissociated from muscle mass16. Weakness of the quadriceps muscle is observed early in the disease process and may precede disease onset17,18. The early manifestation
of strength loss in patients with OA suggests that pain and atrophy from disuse cannot fully explain the reported muscle weakness, and that other cellular factors may play a role.

Muscle fiber type composition (i.e., the distribution of slow-contracting/oxidative muscle fibers vs fast-contracting/glycolytic muscle fibers) is a powerful indicator of global muscle health. In general, the presence of “hybrid” muscle fibers co-expressing Type IIa fast-twitch and Type IIX super-fast twitch (Type IIa/x) myosin heavy chain (MyHC) is indicative of poor muscle health and may contribute to impaired muscle function. Limited work in orthopedic populations, such as those with anterior cruciate ligament (ACL) reconstruction, indicates that knee joint injury results in unfavorable slow-to-fast fiber type transitions in the vastus lateralis that are not reversed after rehabilitation. In people with advanced-stage knee OA, a high prevalence of hybrid fibers has also been reported in the vastus lateralis. The precise mechanisms that mediate fiber type transitioning are still being explored; however, elucidating whether fiber type transitioning is a consequence of early disease pathology, or is secondary to atrophy and/or inactivity is important for understanding the etiology of muscular deficits in people with OA.

Although contractile components of muscle fibers (e.g., MyHCs) are fundamental for determining overall muscle function other components within the muscle also play an important role in force transmission and contractile performance. For instance, the amount of extracellular matrix (ECM), or non-contractile tissue, within skeletal muscle can negatively affect whole muscle strength. Pathological conditions are often characterized by excessive ECM accumulation, which results in poor muscle quality. Whether fibrotic deposition contributes to muscle dysfunction in OA is unknown. Specialized cell populations such as muscle stem cells, called satellite cells, are responsible for muscle repair and regeneration, but also play an important role in regulating the ECM. It is conceivable that alterations to the ECM and/or satellite cells in moderate OA may contribute to muscle strength deficits that occur independent from muscle atrophy.

The purpose of this study was to characterize cellular properties of muscle from individuals presenting with symptomatic moderate radiographic OA. We hypothesized that features other than muscle fiber size, such as increased abundance of IIa/x MyHC hybrid muscle fibers, elevated profibrotic gene expression and ECM content, and/or decreased satellite cell density may contribute to functional deficits in OA. Cellular-level insight can help guide early preventative countermeasures for strength loss with OA, thereby improving muscle performance and quality of life at the onset of disease. Identifying muscular perturbations in early-stage OA may also help develop targeted therapeutics for treating profound muscle weakness observed in late-stage OA.

Methods

Study subjects and muscle biopsies

Subjects provided their written informed consent from a protocol approved by the institutional review board at the University of Kentucky and Wake Forest University, in accordance with the Declaration of Helsinki. Subjects with OA for the present study were recruited from those entering the Strength Training for Arthritis Trial (START) at Wake Forest University. Complete details of the study including the inclusion and exclusion criteria have been published. Briefly, OA subjects had to be ambulatory and over 55 years of age with knee pain and mild-moderate radiographic knee OA based on semi-flexed knee radiographs with grade II or grade III OA on the Kellgren Lawrence (KL) scale. Subjects with lateral > medial tibiofemoral OA or patellofemoral OA of grade 3 on a 0–3 scale (assessed using the sunrise view of the patellofemoral joint) were excluded. Special care was taken to ensure that healthy, control subjects were similar to OA subjects in regard to activity, age and BMI; however, no matching was performed. Control subjects underwent the same standing semi-flexed bilateral anteroposterior and patellofemoral x-rays as the subjects with OA and had to have a KL grade of ≤ 1 in both knees and no evidence of patellofemoral OA. To maintain consistency, the same rheumatologist (RFL) read all x-rays. Activity level in both groups was assessed by the Physical Activity Scale for the Elderly (PASE). Comparable healthy control subjects were from the University of Kentucky Center for Muscle Biology: Normal Tissue Bank.

Vastus lateralis muscle biopsies were obtained via the Bergstrom technique and processed for analyses. For RNA, muscle (~100 mg) was immediately frozen in liquid nitrogen followed by storage at –80°C until RNA extraction was performed. For histology/immunohistochemistry (IHC), muscle samples (~50 mg) were cleaned of fat and connective tissue, then mounted onto a piece of cork with mounting medium (1 part tragacanth (VWR):1.5 part cool isopentane and stored at –80°C until sectioning. Usable muscle mounts for IHC were obtained from 15 control and 20 OA subjects.

Strength measurements

Maximum unilateral concentric isokinetic quadriceps strength was measured using a HUMAC NORM isokinetic dynamometer (CSMl, Stoughton, MA, USA). Knee extensor strength was tested through a joint arc from 90° to 30° of knee flexion. The average force was calculated between joint angles of 40–80°. Trials were spaced by rest periods of 30–60 s. The three maximal reproducible trials were averaged from five trials for each test.

Quantitative real-time rtPCR

Muscle biopsy RNA was extracted by homogenizing frozen samples in QIAzol Lysis Reagent (QIAGEN, Hilden, Germany, 79306) and RNA was precipitated and washed using the RNeasy kit (QIA-GEN, 74104). RNA quality and integrity was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). High quality RNA was obtained from 15 control subjects and 22 OA subjects. Reverse transcription was performed with the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, 170-8890). Quantitative real-time reverse transcription polymerase chain reaction (rtPCR) was performed using SYBR Select Master Mix (Thermo-Fisher, 4472908). Gene expression was normalized to the geometric mean of four housekeeping genes: 18S RNA, β-actin (ACTB), β-2 microglobulin (B2M), and Phosphoglycerate kinase (PGK1), using the 2ΔΔCt method. Primer pairs are presented in Supplemental Table 1.

Histology and IHC

Frozen muscle mounts were sectioned at −23 to −25°C. Sections from 15 control and 20 OA subjects were cut at 7 μm, mounted onto charged slides and allowed to air-dry at room temperature for at least an hour prior to storing at −20°C. Prior to staining, slides were removed from −20°C and air dried at room temperature for 10–15 min. All samples were subject to all IHC analyses. However, IHC staining of certain samples was unsuccessful for some analyses; therefore, sample sizes vary by staining procedure.
Fiber typing and cross sectional area (CSA) measurements were performed as follows. Briefly, sections were rehydrated with phosphate buffered saline (PBS) followed by overnight incubation with isofrom-specific MyHC primary antibodies against: Type I (1:100) (Developmental Studies Hybridoma Bank (DSHB), Iowa City, IA, USA; BA.D5 concentrate), Type Ila (neat) (DSHB, SC.71 supernatant), Type IIX (neat) (DSHB, 6H1 supernatant) and Laminin (1:100) (Sigma Aldrich, St. Louis, MO, USA; L9393). Sections were washed then incubated for 1 h with fluorophore conjugated secondary antibodies (1:200): goat anti-mouse (GtMs IgG2b AlexaFluor647 (A-21242), GtMs IgG1 AlexaFluor488 (A-21121), GtMs IgM AlexaFluor555 (A-21426)) (Thermo-Fisher, Carlsbad, CA, USA) and GtZrab (rabbit) AMCA (Vector Laboratories, Burlingame, CA, USA; Cl-1000). Sections were washed, post-fixed in methanol and cover slipped with Vectashield Mounting Medium (Vector Laboratories, H-1000).

For fiber type-specific satellite cell analysis, sections were fixed in ice cold (−20 °C) acetone and washed with PBS. Endogenous peroxidases were blocked with 5% hydrogen peroxide. Sections were then blocked for 1 h in 2.5% normal horse serum (NHS) (Vector Laboratories, S-2012) followed by overnight incubation with primary antibodies against: Pax7 (1:100) (DSHB, Pax7 concentrate), Type I MyHC (1:75) (DSHB, BA.D5 concentrate) and Laminin (1:100) (Sigma Aldrich, St. Louis, MO, USA; L9393). Sections were washed and incubated with GtMs IgG1 b10n (1:1000) (Jackson ImmunoResearch Laboratories, West Grove, PA, USA; 115-065-205) for 90 min, followed by four washes then a 1 h incubation with: streptavidin horsenaserdase peroxidase (1:500) (Thermo-Fisher, S-911; 2.5 µg/µl stock), GtZrab IgC AlexaFluor488 (1:250) (Thermo-Fisher, A-11034 and GtZMs IgG2b AlexaFluor555 (A-21426) (Thermo-Fisher, A-21242). Sections were incubated for 20 min with TSA AlexaFluor594 (1:200) in amplification diluent (Thermo-Fisher, T20950), washed and cover slipped with Vectashield with DAPI to visualize nuclei (Vector Laboratories, H-1200).

Wheat Germ Agglutinin (WGA), which binds to glycosaminoglycans, was used to quantify ECM. Sections were fixed for 20 min with 4% paraformaldehyde, washed with PBS, and incubated with Texas Red conjugated WGA (1:50 of 1 mg/ml) for 2 h (Thermo-Fisher, W21405). Sections were then washed and cover slipped with Vectashield. Collagen I and III content in the ECM was assessed using Sirius Red staining. Sections were fixed in 0.1% Sirius red in saturated picric acid for 2 h and incubated with 0.1% Sirius red in saturated picric acid for 2 h (Electron Microscopy Sciences (EMS), Hatfield, PA, USA, 26357-02). Following Sirius red staining, sections were washed in 0.5% acetic acid in distilled water, dehydrated with 95% then 100% ethanol (1–3 dips each) and equilibrated for 10–15 min in Xylenes. Slides were mounted with Cytoseal 60 (EMS, 18007).

Image capture and quantification

Fluorophores were imaged using an AxiosImager M1 (Zeiss; Oberkochen, Germany), and brightfield images were acquired with an Olympus BX61VS (Olympus; Shinjuku, Tokyo, Japan). Muscle CSA was determined by manually outlining muscle fibers on entire cross sections using Zen image analysis software (Zeiss). Fiber type distribution was quantified manually by a trained technician. All event counts were collected in Zen. Threshold analysis of WGA and Sirius Red staining was done according to previously published methods. Briefly, for WGA analysis, regions of interest (ROI) that did not include fibrotic swathing were chosen (at least three ROIs/sample), a background correction was applied, and images were converted to grayscale. A threshold of 0–215 was used for each image and the percent of the total ROI area positive within the threshold was measured. For fibrotic swathing, images were given a generic label and two blinded, independent researchers were asked to rank biopsies from most swathing (23) to least swathing (1). We then compared swath rankings to the percentage of WGA + area. For Sirius Red analysis, whole section images were acquired, uploaded into Photoshop (Adobe, San Jose, CA, USA), and non Red + pixels were selected then deleted. Images were then opened in Image J and ROIs were chosen. ROIs were converted to grayscale and the Sirius Red + area was measured by threshold as described above. Satellite cells were identified as Pax7+/DAPI+ and expressed relative to fiber number. To identify satellite cells associated with specific fiber types, satellite cells located under the laminin border of each fiber type (MyHC Type I or I1) were counted.

Rigor and reproducibility

A number of steps were employed to enhance the scientific rigor of the experiments. Rigor between Wake Forest University and the University of Kentucky was maintained through onsite review of muscle strength and standardized biopsy protocols. In addition, the same techniques and equipment were used at both sites. Control subjects were chosen to represent a similar activity level, age range and BMI of OA subjects. Isotype, no primary antibody and negative and positive controls were performed in each experiment to validate results, minimize non-specific background staining and tissue autofluorescence, and assure antibody specificity, sensitivity, and lack of cross-reactivity. Quantification was semi-automated and analyses were performed blinded to study design. Operators were spot checked with characterized tissue samples to minimize inter-analysis and inter-individual variability and assure reproducibility.

Statistical analysis

The assumption that data were sampled from a Gaussian distribution was tested using D’Agostino-Pearson normality test. For all analyses except PCR, data was found to be normally distributed, warranting the use of a parametric t test. Since no matching was performed an unpaired t test was chosen. Additionally, no assumption of equal variances was made and groups had unequal sample sizes, so Welch’s correction was applied. Differences in all muscle characteristics between control and OA groups were analyzed by unpaired t tests with Welch’s correction. Pearson’s product moment correlations were used to determine relationships of muscle characteristics to muscle strength. Gene expression data (PCR) did not pass the D’Agostino-Pearson normality test, warranting the use of nonparametric statistical test. A Mann–Whitney U test was used to determine differences in relative mRNA expression between control and OA groups and Spearman Rho correlation was used to analyze the relationship of relative mRNA expression to Sirius red staining and knee extensor strength. Statistical analyses were performed using Prism 7 (GraphPad Software Inc, La Jolla CA).

All normally distributed data are expressed as mean ± 95% Confidence Interval (CI). Gene expression data is shown as median and interquartile range (IQR). All tests were two-tailed, p < 0.05.

Results

Thirty-nine subjects participated in this study: 24 with OA and 15 healthy controls. Group demographics are presented in Table I.

<table>
<thead>
<tr>
<th>Measure</th>
<th>Healthy control (CON)</th>
<th>OA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>63.7 ± 6.9, 53.9–74.3 years</td>
<td>60.2 ± 5.5, 52.0–73.0 years</td>
</tr>
<tr>
<td>BMI</td>
<td>26.9 ± 2.6, 23.3–34.2 kg/m²</td>
<td>28.4 ± 3.9, 20.6–37.5 kg/m²</td>
</tr>
<tr>
<td>Sex</td>
<td>F = 10; M = 5</td>
<td>F = 10; M = 14</td>
</tr>
</tbody>
</table>
Similarly, activity level was not statistically different between OA and control groups, determined by PASE (160.4, 123.0–197.8 vs 175.3, 143.0–209.7, \( P = 0.507 \)) [Fig. 1(A)]. However, OA subjects had significantly weaker quadriceps than the control subjects (62.23, 50.67–73.8 Nm vs 91.46, 75.91–107.0 Nm, \( P = 0.003 \)) [Fig. 1(B)]. Despite quadriceps weakness, there was no significant difference in muscle fiber CSA or fiber type-specific CSA [Fig. 1(C) and (D)]. OA patients had significantly fewer Type I muscle fibers (41.51, 35.56–47.47% to vs 53.07, 44.86–61.29%, \( P = 0.02 \)) [Fig. 1(E) and (F)]. Fewer Type I fibers coincided with a greater percentage of

**Fig. 1.** Subjects with mild to moderate radiographic and symptomatic OA have reduced quadriceps strength in the absence of muscle atrophy. A) PASE results showing comparable activity levels between control (CON, \( n = 15 \)) and OA (\( n = 24 \)) subjects. B) Quadriceps strength measured by knee extensor. CON (\( n = 15 \)), OA (\( n = 24 \)); *\( P = 0.0034 \). C) CSA of all fibers within muscle biopsies. CON (\( n = 15 \)), OA (\( n = 20 \)). D) CSA classified by fiber type. CON (\( n = 15 \)), OA (\( n = 20 \)). E, F) Immunohistochemical analysis of fiber type distribution; MyHC Type I is pink, IIa is green, IIa/x is orange, and Laminin is blue. CON (\( n = 15 \)), OA (\( n = 20 \)). Type I fibers, *\( P = 0.0222 \); Type IIa/x fibers, *\( P = 0.0091 \). Representative images were obtained at 20×. Scale bars = 100 μm. All data are expressed as mean ± 95% CI, analyzed by unpaired t test with Welch’s correction.
hybrid fibers co-expressing Ila and Ilx MyHC isoforms (Type Ila/x) (24.61, 20.61–28.61% vs 16.4, 11.6–21.2%, P = 0.009) [Fig. 1(E) and (F)]. Fiber CSA positively correlated to quadriceps strength in both OA and control (r = 0.51, 0.22–0.72, P = 0.002) [SFig. 1(A)]. This correlation was significant for both Type I (r = 0.34, 0.003–0.602, P = 0.048) and Ila (r = 0.52, 0.23–0.73, P = 0.001) fibers, but not hybrid Ila/x fibers (r = 0.26, –0.08 – 0.55, P = 0.129) [Fig. 1(B) and (C)]. The percentage of hybrid Ila/x fibers negatively correlated to strength (r = –0.35, –0.61 to –0.02, P = 0.039) [SFig. 1(D)]. Hybrid Type I/Ilb fibers were present in muscles from both OA and control groups, but were rare (<2% of total fibers), and thus excluded from analyses [SFig. 1(E)].

A significantly greater percentage of muscle area positively stained with WGA in OA muscles compared to control (7.33, 5.98–8.67 % of area vs 4.70, 3.74–5.65 % of area, P = 0.002) [Fig. 2(A)]. In addition, large swaths of fibrotic (WGA+) tissue were observed in several OA subjects [Fig. 2(B)]. We found that biopsies with the most WGA + ECM surrounding individual muscle fibers also had the greatest fibrotic swathing (r = 0.88, 0.74–0.95, P < 0.0001) [Fig. 2(C)]. Areas of WGA + fibrotic swathing also contained collagen, staining positive with Sirius Red [SFig. 2(A)]. Similar to WGA staining, the percentage of Sirius Red + area surrounding muscle fibers was significantly elevated in OA muscles (4.34, 3.88–4.79 % of area vs 3.31, 2.83–3.79 % of area, P = 0.002) [Fig. 3(A) and (B)], and samples with more Sirius Red + area had higher average swath rankings (r = 0.58, 0.22–0.81, P = 0.004) [SFig. 2(B)]. Subjects with more Sirius Red + muscle area also had weaker quadriceps (r = –0.55, –0.76 to –0.25, P = 0.001) [Fig. 3(C)]. Fibrotic swathing also correlated to strength, where samples with higher average swath ranks had weaker quadriceps (r = –0.40, –0.70 to 0.01, P = 0.056) [SFig. 2(C)].

The distributions of gene expression for both Connective Tissue Growth Factor (CTGF) (4.37, 3.36–6.56 vs 1.915, 1.71–3.87, P = 0.007) and Transforming Growth Factor beta (TGFβ) (21.21, 10.25–47.91 vs 6.99, 1.93–18.76, P = 0.015) differed in the vastus lateralis of OA subjects relative to control subjects [Fig. 4(A)]. The expression levels of both CTGF and TGFβ mRNAs positively correlated to the percentage of Sirius Red + muscle area (r = 0.54, 0.22–0.76, P = 0.002 and r = 0.45, 0.099–0.697, P = 0.012 respectively) [Fig. 4(B)]. Subjects with higher levels of CTGF and TGFβ also had weaker quadriceps (r = –0.61, –0.78 to –0.34, P < 0.0001 and r = –0.45, –0.683 – 0.142, P = 0.005 respectively) [Fig. 4(C)].

Satellite cell density (Pax7 + per 100 fibers) was significantly reduced with OA relative to control (6.87, 5.79–7.95 vs 10.25, 8.44–12.06, P = 0.002) [Fig. 5(A) and (B)], primarily due to a reduction in satellite cells associated with Type II muscle fibers in OA patients (5.297, 4.30–6.30 vs 7.13, 5.96–8.29, P = 0.017).
There was a trend toward a reduction of satellite cells associated with Type I fibers as well; however, this reduction was not statistically significant (9.20, 7.56 e 10.84 vs 11.75, 9.38 e 14.12, P = 0.068) [Fig. 5(C)]. Overall satellite cell density inversely correlated to the percentage of Sirius Red+ muscle area (r = −0.41, −0.68 to −0.06, P = 0.026) [Fig. 5(D)]. This correlation was also significant for Type I (r = −0.41, −0.68 to −0.06, P = 0.026) and Type II satellite cells (r = −0.44, −0.70 to −0.09, P = 0.016) [Fig. 5(E)] individually.

Discussion

The purpose of this study was to establish a cellular and molecular profile that provides insight into the pathology of muscle weakness resulting from mild to moderate radiographic and symptomatic knee OA. Muscle fiber CSA was similar in OA subjects compared to activity- and age-matched controls, but quadriceps strength was lower in the OA subjects. OA patients had fewer Type I fibers and more hybrid IIa/x fibers compared to healthy controls, pointing to a pathologically-mediated fiber type transition. OA subjects also presented with significantly more ECM, which may contribute to comparatively lower muscle strength. Fewer satellite cells in OA subjects, concomitant with greater profibrotic gene expression, is consistent with expanded ECM. This study provides the first cellular evidence for reduced whole muscle quality in moderate OA. This information may help guide future therapeutics aimed at reducing OA-mediated muscle weakness and dysfunction.

Only one previous report has assessed fiber type frequency in OA subjects relative to controls20. In agreement with our findings, the authors showed significantly more Type IIa/x hybrid fibers in OA. Additionally, we observed fewer Type I fibers in OA muscles relative to controls. Shifts in the frequency of muscle fiber types with OA are not without functional implications, as ~50% of the muscle fibers in a healthy vastus lateralis are Type I. A slow-to-fast fiber type transition could affect the performance of activities that require submaximal efforts 33. A preponderance of Type IIa/x hybrid fibers is generally associated with disuse-mediated atrophy34 and/or sedentary behavior18. However, since atrophy was not apparent in these OA subjects and activity level was the same relative to controls, these data indicate that the observed fiber type transition has a different etiology. Following extensive rehabilitation and recovery after ACL injury, elevated Type IIa/x fiber percentage persists in the vastus lateralis, suggesting that knee joint alterations may result in persistent and pathological fiber type changes within the muscle19. Interestingly, we found that Type IIa/x percentage negatively correlated with quadriceps strength. Type IIa/x expression could point to early denervation events, which may contribute to muscle weakness28. Neurogenic muscle atrophy and subsequent fiber type grouping has also been shown in end-stage OA35. While more work is necessary to determine the cause of OA-mediated fiber type transitioning, it appears that the OA fiber type profile is symptomatic of intrinsic pathological changes within the muscle, and could contribute to overall muscle dysfunction.
In contrast to previous reports in end-stage knee OA, muscle fiber atrophy does not appear characteristic of moderate OA. However, we report for the first time that ECM is significantly expanded in subjects with moderate OA relative to controls, potentially limiting the regenerative capacity of the muscle. In support of this, we found a negative association between quadriceps strength and fibrotic collagen deposition. In agreement with these findings, it was recently shown in an animal model that excessive fibrosis can impair whole muscle strength. Furthermore, differences in gene transcription of CTGF and TGFβ in OA patients suggest a signaling pathway potentially activated in OA that may contribute to increased fibrosis. TGFβ is a hormone-like cytokine that is a key regulator of ECM remodeling, and CTGF cooperates with TGFβ to promote collagen production from fibroblasts. Collectively, these data suggest that mild to moderate radiographic OA is characterized by a pro-fibrotic environment. We speculate that the pro-fibrotic milieu in this stage of OA may contribute to atrophy that manifests in the later stages of OA.

Whether physical training is able to reverse or slow the accumulation of collagen in the ECM is not yet known. OA-mediated ECM deposition could potentially influence the results of intervention programs in this population, which emphasizes the need for early treatment of OA.

Satellite cell density was significantly lower in subjects with OA, and overall muscle collagen content was inversely related to satellite cell density. Evidence from animal models indicates a strong...
reciprocal relationship between satellite cells and ECM components, particularly fibroblasts and the collagens they secrete. The current study provides the first human evidence that fewer satellite cells is associated with greater collagen content. In addition to ECM alterations, changes in satellite cell density in OA patients could affect skeletal muscle adaptive potential and limit the effectiveness of strength training interventions. A significant reduction in Type II satellite cell density with OA could also contribute to Type II specific impairments observed in late stages of OA. Recent work has suggested that satellite cell phenotype may dictate the regenerative potential of muscle in patients with OA. Along with decreased satellite cell abundance, alterations in the phenotype of satellite cell populations may be an important contributing factor to muscle alterations in late stage OA. Therapeutic targets that address satellite cell phenotype, abundance and ECM deposition may prove effective at increasing quadriceps strength within this cohort.

This study is not without study design constraints and limitations. As this study is cross sectional nature we are unable to establish a cause and effect relationship between the observed cellular alterations in muscle and subsequent atrophy in later stages of the disease. Further we acknowledge that while the subjects had similar PASE scales it is possible that there could be variation in the amounts and types activities the two groups were selecting. Future work, matching subjects using activity trackers maybe one method of addressing this limitation. Lastly, due the small sample size there were wide CIs for some of the performed analyses.

Our findings emphasize the need for more in depth studies extending beyond muscle atrophy to improve our understanding of alterations within the quadriceps in early OA. Determining cellular changes within muscle that contribute to the weakness associated with OA is fundamental to the development of effective therapeutic interventions that can increase the force generating capacity of the quadriceps and counteract pathology. These interventions may also have an important chondroprotective effect on an already damaged joint. Future studies should consider the effects of the cellular adaptations reported here on whole muscle properties such as endurance and power.
Author contributions
All authors aided in revising this manuscript for intellectual content and approved the final version to be published. B. Noehren, K. Kosmac, and K. Murach drafted the article.

Study design: B. Noehren, K. Kosmac, SP. Messier, RF. Loeser, and CA. Peterson.

Subject recruitment and sample collection: All authors.

Data acquisition: B. Noehren, K. Kosmac, RG. Walton, SP. Messier, and RF. Loeser.


Competing interests
The authors have no competing interests.

Role of funding source
This study was supported by National Institutes of Health grants 3R01AR059105-03S1, AR062069, and UL1TR000117. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Acknowledgements
The authors thank Ryan Williamson, Colleen Benish, and Seth Walsh Blackmore for assistance with WGA staining and muscle CSA analysis. The authors also thank Doug Long for recruitment and testing of subjects at the University of Kentucky Center for Muscle Biology. The authors also thank Jovita Newman, START project manager at Wake Forest University, for facilitating the coordination and processing of data between the two testing sites. Lastly, the authors would like to thank Daniel Beavers from Wake Forest University for the statistical advice and manuscript review.

Supplementary data
Supplementary data related to this article can be found at https://doi.org/10.1016/j.joca.2018.05.011.

References


